The use of antiretroviral agents in patients with renal insufficiency

AIDS Patient Care and STDs

Volumn 13, Issue 9, 1999, Pages 517-526

  Ostrop, Nikola J ^a,c   Burgess, Ellen ^b   Gill, M John ^a,b  

^a Southern Alberta HIV Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c Southern Alberta Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DIALYSIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; PRACTICE GUIDELINE;

EID: 0032871249     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.1999.13.517     Document Type: Article

References (71)

1. Stone HD, Appel RG. Human immunodeficiency virus-associated nephropathy: Current concepts. Am J Med Sci 1994;307:212-217.
2. Esforzado N, Feliz T, Almirall J, et al. Nephropathy in human immunodeficiency virus infection. Medicina Clinica 1992;98(abstract):764-767.
3. Buyukbabani N, Durrbach A, Chauveau D, et al. Nephropathies and HIV infection. Anatamo-clinical study. Nephrologie 1993;14(abstract):143-149.
4. Stricker RB, Man KM, Bouvier DB, Goldberg DA, Meniola AE. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet 1997;349:1745-1746.
5. Berns JS, Cohen RM, Silverman M, Turner J. Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases. Am J Kidney Dis 1997;30:558-560.
6. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. Updated recommendations by the International AIDS Society - USA panel. JAMA 1998;280:78-86.
7. BHIVA Guidelines Co-ordinating Committee. British HIV Association Guidelines for Antiretroviral Treatment of HIV seropositive Individuals. Lancet 1997; 349:1086-1092.
8. Hammer SM, Squires KE, Hughes MD, et al. and the ACTG 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-733.
9. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with Ritonavir [abstract LB6a]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections. Washington, DC: IDSA Foundation of Retrovirology and Human Health, 1996:162.
10. Stellbring HJ and the Invirase International Phase III Trial (SV-14604) Group. Clinical and survival benefit of saquinavir in combination with Zalcitabine and Zidovudine in untreated/minimally treated HP/-infected patients [abstract 212]. In: Abstracts of the Sixth European Conference on Clinical Aspects and Treatment of HIV-infection. Hamburg, Germany: European AIDS Clinical Society, 1997:21.
11. Gill J, Lacey L, Gibson A, and the CEASAR Coordinating Committee. Reduction in healthcare resource use in patients with HIV-1 receiving 3TC in addition to their current Zidovudine-containing treatment [abstract 218]. In: Abstracts of the Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, Germany: European AIDS Clinical Society, 1997:23.
12. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:4101-4105.
13. Hood S, Evans J, Bonington A, Denning DW. Decreasing incidence of oropharyngeal Candidiasis in an HIV cohort following the introduction of proteinase inhibitors [abstract I-28]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:248.
14. Jouan M, Cambau E, Baril L, et al. Decreased incidence of disseminated MAC infection in 689 AIDS patients receiving antiretroviral treatment with protease inhibitors [abstract 1-30]. In: Progam and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:248.
15. Baril L, Jouan M, Caumes E, Mengual X, Bricaire F, Katlama C. The impact of highly active antiretroviral therapy on the incidence of CMV disease in AIDS patients [abstract I-31]. In: Program and Abstracts of the 37th Inerscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:248.
16. Goguel J, Katlama C, Sarfati C, Maslo C, Bissuel F, Molina JM. Remission of AIDS-associated intestinal microsporidosis with combined antiretroviral therapy [abstract I-32]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:248.
17. Torriani FJ, Macdonald JC, Karevellas M, Freeman WR. Lack of progression after discontinuation of maintenance therapy for Cytomegalovirus Retinitis in AIDS patients responding to highly active antiretroviral therapy [abstract I-33]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:249.
18. Albrecht H, Huffman C, Degen O, et al. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy [abstract I-34]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:249.
19. Le Moing V, Bissuel F, Costagliola D, et al. Decrease of intestinal cryptosporidosis prevalence in HIV-infected patients concomitant to diffusion of protease inhibitors [abstract I-38]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:249-250.
20. Condra JH, Emini EA. Preventing HIV-1 Drug Resistance. Sci Med 1997 Jan/Feb;14-23.
21. McMahon DK, Mellars JW. Resistance and cross-resistance to protease inhibitors. HIV 1997;6:9-14.
22. Mayers DL. Resistance and cross-resistance to nucleoside reverse transcriptase inhibitors. HIV 1997;6: 15-21.
23. Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics. Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics, Inc., 1992:8-1-49.
24. Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmcokinet 1997;32:30-57.
25. Bennett WM, Aronoff GR, Golper TA, et al. Drug prescribing in renal failure. Philadelphia, PA: American College of Physicians, 1987:1-9.
26. Sanford JP, Gilbert DN, Moellering RC, Sande MA. Drug dosage adjustments in renal and/or hepatic dysfunction. In: Sanford JP, Gilbert DN, Moellering RC, Sande MA, eds. The Sanford Guide to HIV/AIDS Therapy. Vienna, VA: Antimicrobial Therapy Inc., 1997:113-116.
27. Bristol-Myers Squibb. Didanosine (Videx®) Product Monograph. October 1991, reviewed 1998.
28. Singlas E, Taburet AM, Borsa Lebas F, et al. Didanosine pharmacokinetics in patients with normal and impaired renal function: Influence of hemodialysis. Antimicrob Agents Chemother 1992;36:1519-1524.
29. Glaxo Wellcome. Lamivudine (3TC®) Product Monograph. December 1995.
30. Bristol-Myers Squibb. Stavudine (Zerit®) Product Monograph. March 1996.
31. Lea AP, Faulds D. Stavudine. A review of its pharmacodynamic and pharmocokinetic properties and clinical potential in HIV infection. Drugs 1996;51: 846-864.
32. Hoffman-La-Roche. Zalcitabine (Hivid®) Product Monograph. Revised 1997.
33. Adkins JC, Peters DH, Faulds D. Zalcitabine. An update of its pharmcodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection. Drugs 1997;53:1054-1080.
34. Glaxo Wellcome. Zidovudine (Retrovir®) Product Monograph, October 1990. Revised September 1998.
35. Kimmel PL, Lew SQ, Umana WO, Li PP, Gordon AM, Straw J. Pharmacokinetics of Zidovudine in HIV-infected patients with end-stage renal disease. Blood Purif 1995;13:340-346.
36. Knupp CA, Hak LJ, Coakley DF, et al. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: Influence of hemodialysis and continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 1996;60:535-542.
37. Luzier A, Morse GD. Intravascular distribution of Zidovudine: Role of plasma proteins and whole blood components. Antiviral Res 1993;21:267-280.
38. Singlas E, Pioger JC, Taburet AM, Colin JN, Fillastre JP. Zidovudine disposition in patients with severe renal impairment: Influence of hemodialysis. Clin Pharmacol Ther 1989;46:190-197.
39. Guardiola JM, Mangues MA, Domingo P, Martinez E, Barrio JL. Indinavir pharmacokinetics in hemodialysis-dependent end-stage renal failure. AIDS 1998; 12:1395.
40. Chugh S, Bird R, Alexander EA. Ritonavir and renal failure. N Engl J Med 1997;336:138.
41. Tashima KT, Horowitz JD, Rosen S. Indinavir nephropathy N Engl J Med 1997;336:138-139.
42. Duong M, Sgro C, Grappin M, Biron F, Boibieux A. Renal failure after treatment with Ritonavir. Lancet 1996;348:(9028)693-694.
43. Witzke O, Plentz A, Schaefers RF, Reinhardt W, Heemann U, Philipp T. Side-effects of ritonavir and its combination with saquinavir and special regard to renal function. AIDS 1997;11:836-838.
44. Asher DP, Lucy MD. Indinavir sulfate renal toxicity in a pediatric hemophiliac with HIV infection. Ann Pharmacother 1997;31:1146-1149.
45. Merck. Crixivan® Product Monograph. September 1996, revised February 1998.
46. Bach MC. Indinavir nephrolithiasis in warm climates. J Acquir Immune Defic Synd Hum Retrovirol 1997; 14:296-297.
47. Kopp JB, Miller KD, Mican JM, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med 1997;127:119-125.
48. Daudon M, Estepa L, Viard JP, Joly D, Jungers P. Urinary stones in HIV-1 positive patients treated with Indinavir. Lancet 1997;349:1294-1295.
49. Sutherland SE, Reigle MD, Seftel AD, Resnick MI. Protease inhibitors and urolithiasis. J Urol 1997;158: 31-33.
50. Polyak B, Henley DB, Maudlin J, Postelnik M, Hirschtick R. The clinical incidence of nephrolithiasis in HIV-positive patients receiving Indinavir [abstract I-183]. In: Program and Abstracts of the 37th Interscience conference on Antimicrobial Agents arid Chemotherpy. Toronto, ON: American Society for Microbiology, 1997:277.
51. Mauss S, Niepmann H, Medwe M, Haeussinger D, Jablonowski H. Increased incidence of nephrolithiasis and flank pain in HIV seropositive individuals treated with Indinavir [abstract I-184]. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON: American Society for Microbiology, 1997:277.
52. Michl G, Herfort O, Walli R, Anders HJ, Goebel FD. Incidence and risk factors of cristalluria in patients treated with Indinavir [abstract 442]. In: Abstracts of the Sixth European Conference on Clincal Aspects and Treatment of HIV-Infection. Hamburg, Germany: European AIDS Clinical Society, 1997:71.
53. Jordan KM, Khaksar S, Davies N, Nelson MR. Renal Colic and Nephrolithiasis associated with Indinavir (Crixivan®) [abstract 738]. In: Abstracts of the Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, Germany: European AIDS Clinical Society, 1997:147.
54. Stek M, Fretz KL, Ikeda LS, Bradstreet DC, McCauley JA. Nephrolithiasis with Indinavir-treated advanced AIDS patients in a large Compassionate Use Program [abstract 440]. In: Abstracts of the Sixth European Conference on Clinical Aspects and Treatment of HIV-Infection. Hamburg, Germany: European AIDS Clinical Society, 1997:70-71.
55. Grunke M, Valerius T, Manger B, Kalden JR, Harrer T. Renal dysfunction in a human immunodeficiency virus-infected patient who was treated with Indinavir. Clin Infect Dis 1997;25:1270-1271.
56. McEvoy GK, Litvak K, Welsh OH, eds. American Hospital Formulary System. Drug Information 1997. Bethesda, MD: American Society of Health-System Pharmacists, Inc., 1997:484-491,508,525.
57. Balani SK, Arison BH, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos 1995;23:266-270.
58. Woolf E, Au T, Haddix H, Matuszewski B. Determination of L-735,524, a human immunodeficiency virus protease inhibitor, in human plasma an urine via high-performance liquid chromatography with column switching. J Chromatogr 1995;692:45-52.
59. Abbott Laboratories. Norvir® Product Monograph. August 1996, revised March 1997.
60. Hoffman-la-Roche. Invirase® Product Monograph. March 1996, revised November 1997.
61. Agouron Pharmaceuticals. Nelfinavir (Viracept®) Package insert. La Jolla, CA: 1997.
62. Shetty BV, Kosa MB, Khalil DA, et al. Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996;40:110-114.
63. Kageyama S, Anderson BD, Hoesterey BL, et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentration of proteins. Antimicrob Agents Chemother 1994;38:1107-1111.
64. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmcokinet 1997;32:194-209.
65. Schetz M, Ferdinande P, Van den Berghe G, Verwaechst C, Lauwers P. Pharmacokinetics of continuous renal replacement therapy. Intensive Care Med 1995;21:612-620.
66. Boehringer Inghelheim. Roxane Laboratories. Nevirapine (Viramune®) Prescribing Information, 1996.
67. Murphy RL, Montaner J. Nevirapine: a Review of its Development, Pharmacological Profile and Potential for Clinical Use. Exp Opin Invest Drugs 1996;5: 1183-1199.
68. McEvoy GK, Litvak K, Welsh OH, eds. American Hospital Forumlary System. Drug Information 1997. Bethesda MD: American Society of Health-System Pharmacists, Inc., 1997:494-497.
69. Drugdex® Editorial Board. Delavirdine (Drug Evaluation Monographs). In: Gelman CR, Rumack BH, Hess AJ, eds. DRUGDEX® System. Englewood, MI-CROMEDEX, Inc., CO: (Edition expires February 1998).
70. Pharmacia and Upjohn. Delavirdine (Rescriptor®) Product Monograph, July 1998.
71. Chaput AJ, D'Ambrosio R, Morse GD. In vitro protein-binding characteristics of Delavirdine and its N-dealkylated metabolite. Antiviral Res 1996;32:81-89.